Yahoo · Sep 2, 2026
RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline
RenovoRx (NASDAQ:RNXT) will use its H. C.
RN
NASDAQ · RNXT
RenovoRx, Inc.
Healthcare · Biotechnology
$1.76
Down-$0.01 (-0.56%)
Updated Sep 12, 2026, 11:25 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 36.39M
- P/E ratio
- -3.41
- Dividend yield
- 0.00%
- 52-week range
- $0.77 – $2.59
- Volume
- 1.17M
- Avg. volume
- 506.07K
Price performance
RNXT price history
1M range · 20 trading sessions · Daily adjusted prices
RNXT closed at $1.76 after 20 trading sessions, up 25.71% for the selected period.
- Last close
- $1.76
- Period change
- +25.71%
- Period low
- $1.17
- Period high
- $2.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1.77 | $1.8199 | $1.67 | $1.76 | 1.17M |
| Sep 10, 2026 | $1.97 | $1.99 | $1.71 | $1.77 | 1.64M |
| Sep 9, 2026 | $2.15 | $2.30 | $1.935 | $1.995 | 1.73M |
| Sep 8, 2026 | $2.31 | $2.345 | $2.1509 | $2.20 | 1.21M |
| Sep 4, 2026 | $2.35 | $2.5396 | $2.28 | $2.39 | 2.09M |
| Sep 3, 2026 | $2.52 | $2.52 | $1.98 | $2.37 | 3.83M |
| Sep 2, 2026 | $2.14 | $2.59 | $2.14 | $2.52 | 4.13M |
| Sep 1, 2026 | $1.91 | $2.20 | $1.83 | $2.11 | 3.31M |
| Aug 31, 2026 | $1.735 | $1.97 | $1.65 | $1.93 | 3.29M |
| Aug 28, 2026 | $1.48 | $1.6788 | $1.4705 | $1.67 | 1.05M |
| Aug 27, 2026 | $1.47 | $1.55 | $1.43 | $1.48 | 428.93K |
| Aug 26, 2026 | $1.41 | $1.55 | $1.3847 | $1.49 | 763.83K |
| Aug 25, 2026 | $1.30 | $1.56 | $1.27 | $1.42 | 1.35M |
| Aug 24, 2026 | $1.33 | $1.3581 | $1.24 | $1.25 | 264.05K |
| Aug 21, 2026 | $1.30 | $1.325 | $1.25 | $1.32 | 233.27K |
| Aug 20, 2026 | $1.29 | $1.35 | $1.23 | $1.32 | 381.18K |
| Aug 19, 2026 | $1.17 | $1.3372 | $1.15 | $1.315 | 582.34K |
| Aug 18, 2026 | $1.21 | $1.2686 | $1.12 | $1.17 | 498.97K |
| Aug 17, 2026 | $1.415 | $1.505 | $1.1799 | $1.20 | 1.22M |
| Aug 14, 2026 | $1.27 | $1.45 | $1.26 | $1.40 | 1.01M |
Latest RNXT news
The latest Smart Investors Daily articles mentioning RNXT.
Stock researchCompany · Overview
RNXT research
Overview
Company profile and research snapshot.
Company profile
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Ascendiant Capital | Buy | — |
| Jun 1, 2026 | Ascendiant Capital | Buy | — |
| Apr 9, 2026 | Ascendiant Capital | Buy | — |
| Apr 8, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 17, 2026 | Ascendiant Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York P
Benzinga · Aug 28, 2026
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $14 to $14.5.
Benzinga · Aug 25, 2026
RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
